Issue Date: January 9, 2017
Lonza to make drug active for Aurinia
Lonza has signed an agreement to manufacture voclosporin for use by the biotech firm Aurinia in a Phase III clinical trial of the drug as a lupus nephritis treatment. Lonza has an option to supply the compound for up to 20 years. Aurinia CEO Charles Rowland says his firm spent years working with Lonza to optimize the drug’s complex manufacturing process.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society